Rohe R - Search Results

1

Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures.

Kiprov DD, Golden P, Rohe R, Smith S, Hofmann J, Hunnicutt J. Kiprov DD, et al. Among authors: rohe r. J Clin Apher. 2001;16(3):130-3. doi: 10.1002/jca.1024. J Clin Apher. 2001. PMID: 11746539

2

Exclusive therapeutic apheresis delivery system.

Kiprov DD, Rohe R, Hofmann J. Kiprov DD, et al. Among authors: rohe r. Transfus Apher Sci. 2003 Apr;28(2):173-9. doi: 10.1016/S1473-0502(03)00007-7. Transfus Apher Sci. 2003. PMID: 12679123 No abstract available.

3

Case Report: Therapeutic and immunomodulatory effects of plasmapheresis in long-haul COVID.

Kiprov DD, Herskowitz A, Kim D, Lieb M, Liu C, Watanabe E, Hoffman JC, Rohe R, Conboy MJ, Conboy IM. Kiprov DD, et al. Among authors: rohe r. F1000Res. 2021 Nov 24;10:1189. doi: 10.12688/f1000research.74534.2. eCollection 2021. F1000Res. 2021. PMID: 35464182 Free PMC article.

4

Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study.

Boada M, Kiprov D, Anaya F, López OL, Núñez L, Olazarán J, Lima J, Grifols C, Barceló M, Rohe R, Prieto-Fernández C, Szczepiorkowski ZM, Páez A. Boada M, et al. Among authors: rohe r. J Clin Apher. 2023 Feb;38(1):45-54. doi: 10.1002/jca.22026. Epub 2022 Oct 28. J Clin Apher. 2023. PMID: 36305459 Free PMC article.

5

Minimizing clearance issues with prone breast patients on Varian linear accelerators through isocenter placement.

Wilson L, Rohe R, Lenards N, Hunzeker A, Tobler M, Zeiler S, Fellows A. Wilson L, et al. Among authors: rohe r. Med Dosim. 2021 Winter;46(4):319-323. doi: 10.1016/j.meddos.2021.03.004. Epub 2021 Apr 24. Med Dosim. 2021. PMID: 33903005

6

Comment on "Improved conjugate view quantitation of I-131 by subtraction of scatter and septal penetration events with a triple energy window method" [Med. Phys. 22, 1637-1643 (1995)].

Rohe RC, Macey DJ. Rohe RC, et al. Med Phys. 1996 May;23(5):765. doi: 10.1118/1.597671. Med Phys. 1996. PMID: 8724751 No abstract available.

7

Biokinetics and dosimetry analysis in healthy volunteers for a two-injection (rest-stress) protocol of the myocardial perfusion imaging agent technetium 99m-labeled Q3.

Rohe RC, Thomas SR, Stabin MG, Deutsch EA, Gerson MC, Cummings DD, Maxon HR 3rd. Rohe RC, et al. J Nucl Cardiol. 1995 Sep-Oct;2(5):395-404. doi: 10.1016/s1071-3581(05)80027-3. J Nucl Cardiol. 1995. PMID: 9420819

8

Comparison of technetium 99m Q12 and thallium 201 for detection of angiographically documented coronary artery disease in humans.

Gerson MC, Lukes J, Deutsch E, Biniakiewicz D, Rohe RC, Washburn LC, Fortman C, Walsh RA. Gerson MC, et al. Among authors: rohe rc. J Nucl Cardiol. 1994 Nov-Dec;1(6):499-508. doi: 10.1007/BF02939972. J Nucl Cardiol. 1994. PMID: 9420743

9

Hemoglobin D Iran alpha A2 beta 22 2-Glu leads to Gln in association with thalassemia.

Rohe RA, Sharma V, Ranney HM. Rohe RA, et al. Blood. 1973 Sep;42(3):455-62. Blood. 1973. PMID: 4725603 Free article. No abstract available.

10

Hematologic screening tests.

Rohe RA. Rohe RA. N Engl J Med. 1973 Apr 26;288(17):913. doi: 10.1056/nejm197304262881718. N Engl J Med. 1973. PMID: 4692911 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters